Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Aytu BioPharma's Net Income for the
three
months ended in Mar. 2026 was $-5.62 Mil. Aytu BioPharma's Revenue for the
three
months ended in Mar. 2026 was $12.41 Mil. Therefore, Aytu BioPharma's net margin for the quarter that ended in Mar. 2026 was -45.27%.
The historical rank and industry rank for Aytu BioPharma's Net Margin % or its related term are showing as below:
LTS:0A8M'
s Net Margin % Range Over the Past 10 Years
Min: -1099.49 Med: -100.67 Max: -15.88
Current: -60.17
LTS:0A8M's Net Margin % is ranked worse than 88.05% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs LTS:0A8M: -60.17
Aytu BioPharma (LTS:0A8M) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aytu BioPharma Net Margin % Related Terms
Aytu BioPharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0A8M vs TXMD, CPHI, RMTI: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma (LTS:0A8M) has a Net Margin % of -45.27% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aytu BioPharma and its competitors. According to the industry distribution chart, Aytu BioPharma ranks #847 out of 962 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is Aytu BioPharma's Net Margin % too high?
Aytu BioPharma's current Net Margin % is -45.27%. Based on the distribution chart, Aytu BioPharma ranks #847 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aytu BioPharma has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Net Margin % compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #847 out of 962 companies for Net Margin %. This places Aytu BioPharma in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current Net Margin % is -45.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Aytu BioPharma (LTS:0A8M) has a current Net Margin % of -45.27%. The stock's GF Value™ is $0.87, compared to a current price of $2.20 — trading 152.9% above its estimated fair value. The current Net Margin % is -45.27%. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aytu BioPharma (LTS:0A8M), the current Net Margin % is -45.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (LTS:0A8M) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.20 is trading 152.9% above its estimated GF Value™ of $0.87.
Key valuation signals for LTS:0A8M:
Net Margin %: -45.27%
GF Value™: $0.87 vs. price of $2.20 (152.9% above fair value)
No single metric tells the full story. See the LTS:0A8M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score
Get the complete analysis for LTS:0A8M
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0A8M has been successfully added to your 
